Toxicity Profile of PEG-Asparaginase in Adult Patients With Acute Lymphoblastic Leukemia in Brazil: A Multicenter Cross-Sectional Study.
Acute lymphoblastic leukemia
Asparaginase
Liver toxicity
Pediatric-inspired regimen
Thrombosis
Journal
Clinical lymphoma, myeloma & leukemia
ISSN: 2152-2669
Titre abrégé: Clin Lymphoma Myeloma Leuk
Pays: United States
ID NLM: 101525386
Informations de publication
Date de publication:
08 2020
08 2020
Historique:
received:
06
02
2020
revised:
31
03
2020
accepted:
01
04
2020
pubmed:
12
5
2020
medline:
21
8
2021
entrez:
12
5
2020
Statut:
ppublish
Résumé
Currently, pediatric-inspired regimens are commonly applied to adults with acute lymphoblastic leukemia (ALL) after the recent recognition that these protocols improve survival. While asparaginase in whatever available formulation is a key component of modern treatment of ALL, many adult oncologists and hematologists struggle to deal with its particular toxicities in clinical practice. We reviewed toxicity outcomes of pegylated asparaginase (PEG-ASP) in adults with ALL treated in 3 reference centers in Brazil. This was a cross-sectional retrospective chart-review study encompassing patients aged 15 years and older diagnosed with ALL or ambiguous-lineage leukemia who received at least one dose of PEG-ASP, regardless of the adopted regimen. A total of 57 patients were included (age range, 15-57 years). Most patients (70%) received 2000 IU/m By reviewing the medical charts of adult patients with ALL from 3 reference centers, we found that our incidence of thrombotic and hepatic adverse events is similar to those reported in other trials involving PEG-ASP. Usually these effects should not preclude further use of the drug because most events are manageable in routine clinical practice.
Sections du résumé
BACKGROUND
Currently, pediatric-inspired regimens are commonly applied to adults with acute lymphoblastic leukemia (ALL) after the recent recognition that these protocols improve survival. While asparaginase in whatever available formulation is a key component of modern treatment of ALL, many adult oncologists and hematologists struggle to deal with its particular toxicities in clinical practice. We reviewed toxicity outcomes of pegylated asparaginase (PEG-ASP) in adults with ALL treated in 3 reference centers in Brazil.
PATIENTS AND METHODS
This was a cross-sectional retrospective chart-review study encompassing patients aged 15 years and older diagnosed with ALL or ambiguous-lineage leukemia who received at least one dose of PEG-ASP, regardless of the adopted regimen.
RESULTS
A total of 57 patients were included (age range, 15-57 years). Most patients (70%) received 2000 IU/m
CONCLUSION
By reviewing the medical charts of adult patients with ALL from 3 reference centers, we found that our incidence of thrombotic and hepatic adverse events is similar to those reported in other trials involving PEG-ASP. Usually these effects should not preclude further use of the drug because most events are manageable in routine clinical practice.
Identifiants
pubmed: 32389674
pii: S2152-2650(20)30179-8
doi: 10.1016/j.clml.2020.04.001
pii:
doi:
Substances chimiques
Antineoplastic Agents
0
Asparaginase
EC 3.5.1.1
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
e523-e528Informations de copyright
Copyright © 2020 Elsevier Inc. All rights reserved.